Advice for Treating Patients With MCL
Simon Rule, MD, PhD, shares his treatment considerations for select patients with mantle cell lymphoma.
Simon Rule, MD, PhD, a professor of hematology at Plymouth University Medical School in the United Kingdom, shares his treatment considerations for select patients with mantle cell lymphoma (MCL).
Rule says that in patients who are young and asymptomatic, his recommended approach is to watch and wait. This approach does not disadvantage the patient, Rule says. He mentions 1 patient in his early 50s that remained untreated for MCL with nodal disease for 12 years.
For patients with aP53mutation, his suggestion is to try a more aggressive strategy, as it will be hard to get them into remission. In these patients, neither autograft or ibrutinib (Imbruvica) will work, so an early allogeneic stem cell transplant may be a good option.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
